Current Environment: Production

Summary

A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.

Conditions

Single Ventricle Heart Disease

Recruitment Status

UNKNOWN

Detailed Description

This is open-label, long-term prospective study in a cohort of Fontan subjects taking drug daily for one year. The study will determine the scope of hepatic stiffness in the cohort by ultrasound and magnetic resonance imaging elastography and evaluate MZ101 pharmacotherapy as a potentially efficacious treatment to reduce liver stiffness.

Eligibility Criteria

Inclusion Criteria:

1. Enrollment in on-going Phase 3 Open-Label Safety Study
2. Informed assent from subject, informed consent from parent/legal guardian as appropriate

Exclusion Criteria:

1. Non-enrollment in the on-going Phase 3 Open-Label Study
2. Subjects with contra-indications for MRI (these subjects will be excluded from the MRI component of this study)
3. Other exclusionary criteria will match those used for the Open-Label Safety Study

Intervention

Intervention Type

Intervention Name

DRUG

MZ101

Gender

ALL

Min Age

12 Years

Max Age

N/A

Download Date

2020-11-24

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

Evaluation of Fontan-Associated Liver Disease NCT03430583

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live person regarding a diagnosis or symptoms, please call the department you are looking for directly or 617-355-6000 or click here to log into your MyChildrens portal.

Quick links:

- Global Services
- Find a Doctor
- Find a Location
- Programs and Services
- Conditions and Treatments
- Request an Appointment